BMY vs LEGN: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BMY is the larger of the two ($121.58B market cap): the incumbent the market prices for continued execution (8.88x forward earnings, beta 0.19). LEGN is the smaller challenger ($2.98B), actually pricier on forward earnings (29.10x): more room to run, but more to prove. If you believe in growth, LEGN fits: analysts expect its revenue to rise 18% next year, against a 3% decline for BMY. If you believe in paying less for profit, BMY fits: it trades at 8.88x forward earnings, against 29.1x for LEGN.
BMY vs LEGN: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMY | LEGN | What it tells you |
|---|---|---|---|
| Market cap | $121.58B | $2.98B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.88 | 29.10 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.19 | 0.55 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 60% of range | 0% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.19 | 2.34 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BMY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BMY and LEGN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and LEGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and LEGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bristol Myers Squibb (BMY) do?
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
What does Legend Biotech (LEGN) do?
Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It develops and commercializes CARVYKTI in a 50/50 profit-and-cost-sharing collaboration with Johnson & Johnson, so Legend's reported revenue shows up largely as collaboration and license income rather than direct product sales. The company also runs an earlier-stage pipeline of other cell therapies and solid-tumor programs, but CARVYKTI drives essentially all of the current commercial narrative. Ingrid Zhang became chief executive effective September 15, 2026.
BMY vs LEGN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BMY drivers: New product portfolio ramp; Oncology and immunology depth.
- LEGN drivers: CARVYKTI commercial ramp; Move to earlier lines of therapy.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For LEGN, legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine.
BMY or LEGN: which should you pick?
If the story you believe is BMY's (New product portfolio ramp), BMY is the more direct way to own it; if it is LEGN's (CARVYKTI commercial ramp), LEGN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and LEGN guides.
BMY vs LEGN: the full fundamentals
BMY. At about $59.43 on November 20, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a fifth straight earnings beat in Q3. The 4.3% dividend yield and strong cash flow are the bull-case anchors, while consensus for only modest 2027 EPS growth (about $6.70 versus $6.45 for 2026) on lower revenue captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $65.
LEGN. LEGN's revenue is recognized mainly as collaboration and license income under the J&J profit split, distinct from CARVYKTI's roughly $710 million of Q3 2026 global net trade sales. At about $15.42 on November 20, 2026 the ADRs trade near 2.2 times trailing sales and about 29 times forward EPS estimates, close to their 52-week low of $15.36, because slowing US growth and competition from anito-cel and bispecifics now weigh on how long the ramp lasts. The 14 covering analysts carry a consensus buy rating and a mean target near $41, though RBC trimmed its target to $50 after the Q3 report and UBS had already cut to $24.
Headline figures (approximate, November 2026): BMY shows revenue (ttm) ~$50.0 billion (Q3 2026 up ~6.9% YoY), q3 2026 adjusted eps $1.35 vs $1.17 consensus, operating margin ~32%, net income (ttm) ~$9.2 billion; LEGN shows revenue (ttm, collaboration/license) ~$1.36B, q3 2026 total revenue ~$359.5M (up ~32% YoY), q3 2026 carvykti net trade sales ~$710M (up ~36% YoY; US +19%, ex-US +86%), q3 2026 net income ~$51.7M.
The bottom line: BMY vs LEGN
BMY and LEGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BMY and LEGN exposure against your real portfolio. It is not an investment adviser.
Wondering how BMY or LEGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Bristol Myers Squibb
Ask Walnut's AI anything about BMY and see how it fits what you own.
FAQ
What is the difference between BMY and LEGN?
+
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMY or LEGN the better stock?
+
Neither is universally better. BMY is the larger incumbent; LEGN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMY or LEGN?
+
On forward P/E (as of November 2026), BMY trades at 8.88x and LEGN at 29.10x, so BMY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMY and LEGN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMY vs LEGN?
+
BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in lower revenue in 2027, with EPS up only about 4%. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $12.6 billion of cash, and litigation exposure, add further uncertainty. LEGN: Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. Gilead's anito-cel, another BCMA CAR-T, has an FDA decision date of December 23, 2026, and Legend has estimated that about 59% of the US CARVYKTI market sits in the fourth-line-plus segment where anito-cel is expected to be labeled; UBS also flagged J&J's Tec-Dara as a threat in earlier lines. US growth already slowed to 19% in Q3 2026 from 32% the quarter before, and Q4 consensus sat at the high end of management's scenarios, so further deceleration is a live risk. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company only reached quarterly GAAP profit in Q2 2026 and its trailing earnings are roughly breakeven, so any sales miss, pricing pressure, or safety signal can move the stock sharply, as the 18% drop on November 10 showed. A new chief executive took over in September 2026. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or LEGN; figures are approximate and dated (as of November 2026). Verify current data before investing.